Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.
about
The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsDiagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation OncologyBone-targeted therapy in metastatic breast cancer - all well-established knowledge?Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.Serum tartrate-resistant acid phosphatase 5b activity as a prognostic marker of survival in breast cancer with bone metastasis.Targeted treatments of bone metastases in patients with lung cancerDirect antitumour activity of zoledronic acid: preclinical and clinical data.The best of both worlds - managing the cancer, saving the bone.Bone health and prostate cancer.Evolving role of bone biomarkers in castration-resistant prostate cancer.A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancerEffects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases.Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancerSurvival benefit of zoledronic Acid in postmenopausal breast cancer patients receiving aromatase inhibitorsBone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.Biochemical markers of bone turnover and clinical outcomes in men with prostate cancerPhase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group.Bone remodeling markers and bone metastases: From cancer research to clinical implicationsBone-targeted agents in the treatment of lung cancer.Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid.Advances in the clinical research of the minimally invasive treatment for the posterior edge of vertebral-body defects by spinal metastasesOnce-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.Current perspectives on skeletal health and cancer progression across the disease continuum in breast cancer-the role of bisphosphonatesCurrent approaches to bone-targeted therapy in genitourinary malignanciesBone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the artInhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid.The role of the bone microenvironment in skeletal metastasis.The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer.Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trialsDiabetic foot osteomyelitis: bone markers and treatment outcomes.Cancer to bone: a fatal attraction.Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology GroupRANKL: A promising circulating marker for bone metastasis responseBones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer.The Usefulness of Bone Biomarkers for Monitoring Treatment Disease: A Comparative Study in Osteolytic and Osteosclerotic Bone Metastasis Models.Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.Collagenous and non-collagenous biochemical markers of bone metastases from prostate cancer.Burden of metastatic bone disease from genitourinary malignancies.Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies.Managing bone health with zoledronic acid: a review of randomized clinical study results.
P2860
Q26750672-C91C0136-895B-4657-9D99-9434AA62C50AQ28076646-5F4A9B01-1E92-4C5C-AC73-047CB7DB8C15Q28087676-7FE83D00-C110-494B-8725-32259AE7E017Q30416847-A94BCB52-AC2E-4323-A90B-D2643E8FE836Q33563273-3C4A7BD7-B5FA-4766-A731-DF47ACF8A02CQ33759713-06D434F7-6697-411B-92A4-167070D7CE5FQ33850938-B5BF959E-25EF-4BD9-B682-4E7870D6E3B9Q33920055-37E9CDA7-F15B-4F26-8D23-186AA6E2AF8BQ33977536-DAE11A8D-70BF-4568-9B73-90296D1E745CQ34023877-09234563-D9ED-44E6-B48A-95290C72C6D9Q34322294-10F51D37-28E0-41E3-8D92-5A061DC27952Q34325491-5B593099-8FE3-4589-918A-848E49637B37Q34613941-46E0A594-C2C6-4D09-A12A-E6A29E5FD641Q34779663-210ED04F-2698-4B04-84D2-9A5995B6B7B3Q34960867-3E89B1A6-3AAA-4B51-8141-C10B7B98AE98Q35022212-DE1D0F2A-DDD7-4067-8380-9DDDC5112EF7Q35051643-1D5C9E7E-5633-4506-BBF2-3B55EC36961CQ35531006-43FD948D-4540-4A20-8AF5-65A0277F7828Q35780792-1E3C8539-6F93-441B-950B-B8DA53099116Q35865726-16946D7A-435D-45A3-88E2-127A33271724Q35948909-7D19B7AA-8BB3-4804-91DF-A0F3881740BEQ36087899-7E03EFB9-3869-481E-9913-2D1AF7283CB6Q36182616-8C9AD8E7-BE33-4682-AF33-3369166BD771Q36231718-AA3C5B5C-51B3-4D9A-88D4-A6E2FC7B1223Q36278556-A6369386-32C1-4CD6-BFAE-2136072EEDC6Q36459367-4C068C44-9E46-434C-B063-8648BCA47FEDQ36491430-2373CA3B-02D2-457D-8455-9C146091A91CQ36491446-886844B9-7AF9-44EE-80C9-E3C164F1F024Q36491479-E3A0BF57-1563-4077-8691-EC4D525A90CFQ36755144-61895689-FE05-4CBB-9BB4-9D5AAAE314C9Q36884628-6D5C5CD9-88FB-42A8-9536-73C9E5850BA8Q36946864-3DEE8959-5177-4B94-9618-D50307C0D3FBQ37288243-7F67DADC-4AB4-443F-B20E-78E8534B25F3Q37355362-C4946F1C-8C7C-4173-8047-D6F9A5A2CC0EQ37648939-5D487D49-0F37-4A11-B6A0-EC79D3DA1EDCQ37724378-18EC44B3-FE86-4D76-9A04-D539AD58C9D6Q37803537-469085C4-2D10-4749-BAFC-84B24F751C50Q37809860-E91F63E0-3D27-4706-B40C-3D7CFC97BE20Q37812612-F3FF6314-1949-4970-97A2-E2F9A2393D84Q37823605-335A5212-F523-4C0A-B5D8-D02CE8DB940B
P2860
Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Normalization of bone markers ...... ion receiving zoledronic acid.
@en
Normalization of bone markers ...... ion receiving zoledronic acid.
@nl
type
label
Normalization of bone markers ...... ion receiving zoledronic acid.
@en
Normalization of bone markers ...... ion receiving zoledronic acid.
@nl
prefLabel
Normalization of bone markers ...... ion receiving zoledronic acid.
@en
Normalization of bone markers ...... ion receiving zoledronic acid.
@nl
P2093
P356
P1433
P1476
Normalization of bone markers ...... ion receiving zoledronic acid.
@en
P2093
Allan Lipton
Evangelos Terpos
Janet E Brown
Patrick Garnero
Pierre Major
Richard Cook
Robert E Coleman
P304
P356
10.1002/CNCR.23529
P407
P577
2008-07-01T00:00:00Z